xiang zhou

xiang zhou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2020 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
MYMin Yao
Min Yao
JLJunmao Li
Junmao Li
MHMingzhen He
Mingzhen He
HOHui Ouyang
Hui Ouyang
LRLulu Ruan
Lulu Ruan
JBjiqing bai
jiqing bai

20 June 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XWXinli Wang
Xinli Wang
ZLZhenggen Liao
Zhenggen Liao
GZGuowei Zhao
Guowei Zhao
WDWei Dong
Wei Dong
XHXiaoying Huang
Xiaoying Huang
XLXin-Li Liang
Xin-Li Liang

19 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JCJie Chen
Jie Chen
XZxiang zhou
xiang zhou
LFLifeng Fu
Lifeng Fu
XHXu Haiyu
Xu Haiyu
Drugs that cure COVID-19 have been marketed; however, this disease continues to ravage the world without becoming extinct, and thus, drug discoveries are still relevant. Since Mpro has known advantages as a drug target, such as the conserved nature of the active site and the absence of homologous proteins in the body, it receives the attention of many researchers. Meanwhile, the role of traditional Chinese medicine (TCM) in the control of epidemics in China has also led to a focus on natural products, with the hope of finding some promising lead molecules through screening. In this study, we selected a commercial library of 2526 natural products from plants, animals and microorganisms with known biological activity for drug discovery, which had previously been reported for compound screening of the SARS CoV-2 S protein, but had not been tested on Mpro. This library contains compounds from a variety of Chinese herbs, including Lonicerae Japonicae Flos, Forsythiae Fructus and Scutellariae Radix, which are derived from traditional Chinese medicine prescriptions that have been shown to be effective against COVID-19. We used the conventional FRET method for the initial screening. After two rounds of selection, the remaining 86 compounds were divided into flavonoids, lipids, phenylpropanoids, phenols, quinones, alkaloids, terpenoids and steroids according to the skeleton structures, with inhibition rates greater than 70%. The top compounds in each group were selected to test the effective concentration ranges; the IC50 values were as follows: (−)–gallocatechin gallate (1.522 ± 0.126 μM), ginkgolic acid C15:1 (9.352 ± 0.531 μM), hematoxylin (1.025 ± 0.042 μM), fraxetin (2.486 ± 0.178 μM), wedelolactone (1.003 ± 0.238 μM), hydroxytyrosol acetate (3.850 ± 0.576 μM), vanitiolide (2.837 ± 0.225 μM), β,β–dimethylacrylalkannin (2.731 ± 0.308 μM), melanin (7.373 ± 0.368 μM) and cholesteryl sodium sulfate (2.741 ± 0.234μM). In the next step, we employed two biophysical techniques, SPR and nanoDSF, to obtain KD/Kobs values: hematoxylin (0.7 μM), (−)–gallocatechin gallate (126 μM), ginkgolic acid C15:1 (227 μM), wedelolactone (0.9770 μM), β,β–dimethylacrylalkannin (1.9004 μM,), cholesteryl sodium sulfate (7.5950 μM) and melanin (11.5667 μM), which allowed better assessments of the binding levels. Here, seven compounds were the winners. Then, molecular docking experiments were specially performed by AutoDock Vina to analyze the mode of interactions within Mpro and ligands. We finally formulated the present in silico study to predict pharmacokinetic parameters as well as drug-like properties, which is presumably the step that tells humans whether the compounds are drug-like or not. Moreover, hematoxylin, melanin, wedelolactone, β,β–dimethylacrylalkannin and cholesteryl sodium sulfate are in full compliance with the “Lipinski” principle and possess reasonable ADME/T properties, they have a greater potential of being lead compounds. The proposed five compounds are also the first to be found to have potential inhibitory effects on SARS CoV-2 Mpro. We hope that the results in this manuscript may serve as benchmarks for the above potentials.

3 November 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XLXin-Yu Li
Xin-Yu Li
LZLi Zhou
Li Zhou
ZJZhen-Hong Jiang
Zhen-Hong Jiang
YLYong Liang
Yong Liang
YFYa-Guo Fan
Ya-Guo Fan
HXHuanhua XU
Huanhua XU
Toxicity has different meanings in traditional Chinese medicine (TCM) and modern toxicology. Integrative toxicology, a novel discipline proposed by our team, offers a robust solution for the scientific elucidation of toxicity in traditional Chinese medicines. Aconitum carmichaelii Debx. (aconite), a classic herbal medicine with a long-standing TCM clinical application history, demonstrates prominent effects in rescuing yang to reverse critical conditions, warming meridians to dispel cold, and tonifying yang to invigorate qi. It is widely used to treat yang deficiency, cold syndromes, and related disorders. However, the dual toxicity-efficacy attribute of aconite has substantially constrained the safety and breadth of its clinical application, leading to its classification as a “high-risk herb.” Thus, this review introduces the concept of integrative toxicology to comprehensively summarize the chemical composition, pharmacological activity, and toxicity mechanisms of aconite. Particular emphasis is placed on various strategies and mechanisms for toxicity attenuation and efficacy enhancement within TCM formulae, including traditional approaches, such as processing and compatibility, as well as potential detoxification pathways identified in modern pharmacological studies. By systematically integrating the framework of integrative toxicology, this work aims to provide a more scientific and secure theoretical basis for the clinical application of aconite, promoting its transformation from a “high-risk herb” to a “controllable therapeutic agent” and thereby maximizing its potential value in modern medicine.

12 May 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XLXin-Yu Li
Xin-Yu Li
LZLi Zhou
Li Zhou
ZJZhen-Hong Jiang
Zhen-Hong Jiang
YLYong Liang
Yong Liang
YFYa-Guo Fan
Ya-Guo Fan
HXHuanhua XU
Huanhua XU
"[Unlike the single active component-dominant mode observed to produce antioxidant and hypoglycemic effects, the antiarrhythmia action of aconite exhibits multi-target characteristics. Both its alcohol extract and water extract demonstrate significant inhibitory effects on ventricular fibrillation, primarily mediated by characteristic C18-and C19-type diterpenoid alkaloids. The specific mechanisms include C18-type diterpenoid alkaloids (e.g., lappaconitine), targeting the regulation of cardiomyocyte Na+ channels. At doses of 0.05-0.15 mg/kg, these diterpenoid alkaloids can suppress the occurrence of premature ventricular beats and ventricular tachycardia. C19-type diterpenoid alkaloids regulate the pathological process of arrhythmia by inhibiting myocardial oxidative stress, modulating mitochondrial energy metabolism homeostasis, and interacting with key biomolecules.]"The original version of this article has been updated.A correction has been made to the section [Page 6, Section 5 Overview of toxicological studies, 5.1 Cardiotoxicity, paragraph 1, line 19, point (2)]:"[(2) Calcium homeostasis mechanism: The sustained opening of Na channels leads to the persistent opening of L-type calcium channels, thereby further triggering intracellular Ca2+ homeostasis imbalance manifested as tachyarrhythmia. Animal experiments demonstrated that 1 μmol/L Aconitum carmichaeliialkaloid promoted Ca2+ influx in rats, while 5 and 10 μmol/L induced ventricular arrhythmia in rat cardiomyocytes (Zhou et al., 2013;Jiang et al., 2021).]"The original version of this article has been updated.A correction has been made to the section [Page 7, Section 5 Overview of toxicological studies, 5.4 Other toxicity, 5.4.1 Neurotoxicity, paragraph 1, line 13, point (2)]: "[(2) Toxicity mechanisms: ① Aconitine was shown to persistently activate voltage-gated sodium channels and inhibit Na+-K+-ATPase activity, leading to abnormal intracellular Na+-ATPase activity, which triggers an imbalance in the homeostasis of intracellular ions, such as Na+, K+, and Ca2+. This process progresses to disrupt both the central and peripheral nervous systems, resulting in symptoms like numbness and tremors.]"The original version of this article has been updated.A correction has been made to the section [Page 8, Section 6 Overview of detoxification research, 6.1 Processes reducing toxicity, paragraph 2, point (4)]:"[Prepared aconite lateral root slices (with glycyrrhiza and black beans): Salt-processed aconite is soaked in clean water to remove salt, then boiled with Glycyrrhiza uralensis (common name: licorice root) and black beans until numbing sensations and bitterness disappear. Glycyrrhiza uralensis and the black beans are removed, then the aconite is sliced thinly and sun-dried. High-temperature steaming destroys the toxic components, while excipients help adsorb and promote the dissolution of toxic constituents.]"The original version of this article has been updated.A correction has been made to the section [Page 9, Section 6 Overview of detoxification research, 6.2 Detoxification by compatibility, 6.2.1 Glycyrrhiza uralensis combined with aconite, paragraph 1,line 21]:"[The flavonoids in Glycyrrhiza uralensis(e.g., glycyrrhizin and liquiritin) can precipitate with the diesterditerpenoid alkaloids in aconite, reducing the leaching of toxic components and slowing the absorption of alkaloids in the intestines. After decocting Glycyrrhiza uralensiswith aconite, the dissolution rate of Glycyrrhiza uralensisflavonoids decreases, likely due to the binding of hydroxyl groups in the flavonoids with the diester-diterpenoid alkaloids.]"The original version of this article has been updated. "[Histopathological observation: Mesaconine can cause histopathological changes in rat liver tissue at specific dose thresholds. After a single oral mesaconine gavage dose of 10 mL/kg to Sprague-Dawley (SD) rats, followed by 4 h of fasting and continuous observation for 2 weeks, the liver of rats in each administration group exhibited fatty vacuoles or degeneration, along with hepatocyte necrosis.]"The original version of this article has been updated.

28 October 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZHZihao Huang
Zihao Huang
ZJZhenhong Jiang
Zhenhong Jiang
SHShaowen Hu
Shaowen Hu
NYNing Ye
Ning Ye
XLXingteng Liu
Xingteng Liu
HXHuanhua XU
Huanhua XU
Traditional Chinese medicine (TCM) formulas, developed through millennia of clinical practice, represent a rich legacy of approximately 100,000 documented prescriptions (99,584 named formula entries in the second edition of the Dictionary of Traditional Chinese Medicine Formulas), yet on average fewer than ten new TCM products were approved annually by China’s NMPA from 2013 to 2024 (77 approvals in total). The experience-based screening paradigm is misaligned with the precision medicine framework demanded by metabolic syndrome (MetS), a multi-target disorder affecting an estimated 1.54 billion adults (95% CrI 1.35–1.76) in 2023. Although artificial intelligence (AI)—encompassing knowledge graphs (KGs), large language models (LLMs), and high-throughput experimentation—has been proposed as a solution, its actual readiness for TCM development remains unclear. This review critically examines KG, LLM, and high-throughput validation technologies enabling precision phytomedicine for MetS, providing a realistic roadmap for AI-driven TCM research and development. The three technology streams exhibit asymmetric readiness. At the stream level, knowledge-graph approaches span Technology Readiness Level (TRL) 3–6, large language model approaches span TRL 1–5, and high-throughput validation platforms span TRL 3–5. LLM development is limited by three TCM-specific hallucination types that lack evaluation benchmarks. KG entity recognition is the most mature component, yet reasoning is hindered by the absence of negative data, missing dose–time dimensions, and unencoded monarch–minister–assistant–envoy hierarchies. High-throughput platforms are technically feasible but remain mismatched to MetS functional endpoints—tumor-derived organoid paradigms show limited direct transferability and would require substantial adaptation. Precision phytomedicine must follow a “foundations before algorithms” sequence: institutionalize negative data, build TCM-Hallu benchmarks, establish functional-endpoint evaluation, and develop AI-assisted regulatory review. Algorithmic advances will remain in an incomplete information space until knowledge infrastructure gaps are closed.